as foreseen in the IMMOMEC project plan, our partners at immatics biotechnologies in Tübingen are currently intensively working on the identification of potential tumor-specific peptide targets for incorporation in the clinical immunomonitoring of the planned phase I trial. This work is a very important part of the IMMOMEC preclinical preparations, and the identified epitopes will hopefully enable us to observe and follow potential changes in tumor-specific immune responses of patients during study treatment.
However, in order to identify relevant target structures on tumor cells, the scientists at immatics heavily depend on the availability of MCC tissue (shock frozen in liquid nitrogen without additives; stored at -70C or lower after initial freezing). As this kind of material is very scarce, we are today contacting you with hopes that you may be able to support these efforts by providing such tumor samples for the mentioned analyses. Therefore, if such samples should be or become available at your hospital, the team at immatics would very much welcome the opportunity to discuss further details with you directly. For this, please do not hesitate to contact Dr. Nina Pawlowski (email@example.com) or myself (firstname.lastname@example.org) at any time.
Thank you for your consideration and kind regards, Jürgen